- Home
- EOLS
EOLS
Evolus Inc.
as 11-15-2024 4:00pm EST
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | 787.7M | IPO Year: | 2018 |
| Target Price: | $22.60 | AVG Volume (30 days): | 672.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.00 - $17.82 | Next Earning Date: | 11-06-2024 |
| Revenue: | $248,326,000 | Revenue Growth: | 34.42% |
| Revenue Growth (this year): | 33.57% | Revenue Growth (next year): | 32.91% |
Stock Insider Trading Activity of Evolus Inc. (EOLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Beaver Sandra | EOLS | Chief Financial Officer | Sep 6 '24 | Sell | $14.98 | 3,276 | $49,074.48 | 148,502 | |
| Yamagishi-Dressler Tomoko | EOLS | Chief Marketing Officer | Aug 30 '24 | Sell | $15.85 | 5,631 | $89,251.35 | 82,375 |
Latest Evolus Inc. News
EOLS Breaking Stock News: Dive into EOLS Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
Simply Wall St.
8 days ago
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Simply Wall St.
9 days ago
Evolus Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
10 days ago
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges
Zacks
10 days ago
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
Business Wire
10 days ago
Evolus Reports Third Quarter 2024 Results
Business Wire
16 days ago
Evolus to Participate in Stifel 2024 Healthcare Conference
MT Newswires
17 days ago
Evolus Gains EU Approval for Estyme Hyaluronic Acid Fillers
Compare EOLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EOLS Evolus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.